Methods and compositions for modulating immune tolerance
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsArya Biragyn, Kouji Matsushima, Dolgor Baatar
Life of this patent
Estimating the term…
Abstract
The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.
Claims22
A pharmaceutical composition comprising a fusion molecule comprising a chemokine receptor ligand and a toxin moiety coupled via a peptide linker, and a pharmaceutically acceptable carrier, wherein the linker has an amino acid sequence comprising:
- amino acids 74 through 89 of SEQ ID NO:
- 2,
- amino acids 74 through 93 of SEQ ID NO:
- 4,
- amino acids 76 through 88 of SEQ ID NO:
- 6,
- amino acids 92 through 99 of SEQ ID NO:
- 8, or
- amino acids 92 through 103 of SEQ ID NO:
- 10,
- wherein the chemokine receptor ligand is a chemokine selected from the group consisting of MC148, I-309, MDC and vMIP-1.
A pharmaceutical composition comprising a fusion molecule comprising a chemokine receptor ligand and a toxin moiety coupled via a peptide linker and a pharmaceutically acceptable carrier, wherein the chemokine receptor ligand is TARC, I-309, MC148, or vMIP-1, and the toxin moiety amino acid sequence consists of amino acids 94 through 435 of SEQ ID NO:
- 4, wherein the linker amino acid sequence comprises:
- amino acids 74 through 89 of SEQ ID NO:
- 2,
- amino acids 74 through 93 of SEQ ID NO:
- 4,
- amino acids 76 through 88 of SEQ ID NO:
- 6,
- amino acids 92 through 99 of SEQ ID NO:
- 8, or
- amino acids 92 through 103 of SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.